Skip to main content
padlock icon - secure page this page is secure

Complete and long‐lasting cytologic and molecular remission of FIP1L1‐PDGFRA‐positive acute eosinophil myeloid leukaemia, treated with low‐dose imatinib monotherapy

Buy Article:

$59.00 + tax (Refund Policy)

Myeloproliferative neoplasms associated with FIP1L1‐PDGFR rearrangements represent a rare subset of myeloid and lymphoid malignancies, characterised by the presence of eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1 genes. The fusion product of such genes is a tyrosine kinase oncoprotein sensitive to imatinib, which to date results to be the standard of care for FIP1L1‐PDGFRA‐positive chronic myeloproliferative disorders with eosinophilia. However, the coexistence of FIP1L1‐PDGFRA rearrangement associated with acute myeloid leukaemia is extremely rare. Here, we report a rare case of FIP1L1‐PDGFRA‐positive acute myeloid leukaemia, with marked peripheral blood and bone marrow eosinophilia, treated with low dose of imatinib monotherapy, achieving a rapid and long‐lasting complete cytologic and molecular remission, without need for intensive chemotherapy.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Acute myeloid leukaemia; FIP1L1‐PDGFRA fusion gen; eosinophilia; imatinib

Document Type: Research Article

Publication date: June 1, 2014

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more